JP2017529397A - Ｘ連鎖性副腎白質ジストロフィーの治療における特異的ｍＴＯＲ阻害剤 - Google Patents

Ｘ連鎖性副腎白質ジストロフィーの治療における特異的ｍＴＯＲ阻害剤 Download PDF

Info

Publication number
JP2017529397A
JP2017529397A JP2017535134A JP2017535134A JP2017529397A JP 2017529397 A JP2017529397 A JP 2017529397A JP 2017535134 A JP2017535134 A JP 2017535134A JP 2017535134 A JP2017535134 A JP 2017535134A JP 2017529397 A JP2017529397 A JP 2017529397A
Authority
JP
Japan
Prior art keywords
mtor
ald
treatment
protein
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017535134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529397A5 (enExample
Inventor
オノフレ、アウロラ プホル
オノフレ、アウロラ プホル
ロベルト、エルウィン クネヒト
ロベルト、エルウィン クネヒト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe
Centro de Investigacion Biomedica en Red CIBER
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe
Centro de Investigacion Biomedica en Red CIBER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL, Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe, Centro de Investigacion Biomedica en Red CIBER filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Publication of JP2017529397A publication Critical patent/JP2017529397A/ja
Publication of JP2017529397A5 publication Critical patent/JP2017529397A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017535134A 2014-09-19 2015-09-21 Ｘ連鎖性副腎白質ジストロフィーの治療における特異的ｍＴＯＲ阻害剤 Pending JP2017529397A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382353.2A EP2997977A1 (en) 2014-09-19 2014-09-19 Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
EP14382353.2 2014-09-19
PCT/EP2015/071563 WO2016042166A1 (en) 2014-09-19 2015-09-21 Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy

Publications (2)

Publication Number Publication Date
JP2017529397A true JP2017529397A (ja) 2017-10-05
JP2017529397A5 JP2017529397A5 (enExample) 2018-11-01

Family

ID=51752074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535134A Pending JP2017529397A (ja) 2014-09-19 2015-09-21 Ｘ連鎖性副腎白質ジストロフィーの治療における特異的ｍＴＯＲ阻害剤

Country Status (7)

Country Link
US (1) US10071063B2 (enExample)
EP (2) EP2997977A1 (enExample)
JP (1) JP2017529397A (enExample)
CN (1) CN107206087A (enExample)
CA (1) CA2961729A1 (enExample)
MA (1) MA39496A (enExample)
WO (1) WO2016042166A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506230A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
JP2021506231A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のために高タンパク質を使用する組成物及び方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
CN108827747A (zh) * 2018-06-04 2018-11-16 华中科技大学苏州脑空间信息研究院 一种多色荧光标记样本的塑性包埋方法
CN115678960B (zh) * 2022-09-13 2024-03-19 澳门大学 一种缓冲液、试剂盒和蛋白酶体检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066430A2 (en) * 2009-11-25 2011-06-03 Duke University Therapeutic agents for neurodegenerative diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US6465627B2 (en) * 1995-07-28 2002-10-15 The Regents Of The University Of California DAX-1 protein, methods for production and use thereof
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
DE60130673T2 (de) * 2000-09-29 2008-07-17 Ethicon Inc. Beschichtungen für medizinische vorrichtungen
ES2303441B1 (es) 2006-05-05 2009-06-22 Fundacio Privada Institut D`Investigacio Biomedica De Bellvitge (Idibell) Uso del acido valproico o de una sal farmaceuticamente aceptable del mismo para la prevencion y/o el tratamiento de la adenoleucodistrofia ligada a x.
TW201035104A (en) 2009-03-27 2010-10-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Improved synthesis method for Temsirolimus and its similar compounds
ES2377381B1 (es) * 2010-05-17 2013-03-14 Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
SG189110A1 (en) * 2010-09-29 2013-05-31 Oxyrane Uk Ltd De-mannosylation of phosphorylated n-glycans
US9670549B2 (en) 2011-11-10 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signatures of neoplasm responsiveness to therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066430A2 (en) * 2009-11-25 2011-06-03 Duke University Therapeutic agents for neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EPERT REV NEUROTHER., 2008, VOL.8 NO.9, P.1367-79, JPN6019033994, ISSN: 0004108431 *
REBECCA DEERING BROSE: "Small molecule induction of the stress proteome and its therapeutic potential", A DISSERTATION SUBMITTED TO JOHNS HOPKINS UNIVERSITY IN CONFORMITY WITH THE REQUIREMENTS FOR THE DEG, JPN6019033993, 2011, ISSN: 0004256038 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506230A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
JP2021506231A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のために高タンパク質を使用する組成物及び方法
JP7410025B2 (ja) 2017-12-20 2024-01-09 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のために高タンパク質を使用する組成物及び方法
JP7434155B2 (ja) 2017-12-20 2024-02-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法

Also Published As

Publication number Publication date
EP3193937A1 (en) 2017-07-26
MA39496A (fr) 2016-03-24
CN107206087A (zh) 2017-09-26
US20170273915A1 (en) 2017-09-28
EP2997977A1 (en) 2016-03-23
US10071063B2 (en) 2018-09-11
CA2961729A1 (en) 2016-03-24
WO2016042166A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
Domínguez-Soto et al. Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis
Shen et al. Activation of p62-keap1-Nrf2 antioxidant pathway in the early stage of acetaminophen-induced acute liver injury in mice
Mondello et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
US12458630B2 (en) Combination therapy for cancer
US20140011761A1 (en) Modulating Endoplasmic Reticulum Stress in the Treatment of Tuberous Sclerosis
WO2019104065A1 (en) Anti-aging methods and compositions
US10071063B2 (en) Specific mTOR inhibitors in the treatment of X-linked adrenoleukodystrophy
US12486537B2 (en) Methods and compositions for diagnosis and management of neurodegenerative diseases
WO2014197835A2 (en) Methods and compositions for the treatment of cancer
HK1244462A1 (zh) 作为用於癌症治疗和诊断之靶标的磷酸甘油酸激酶1的蛋白激酶活性
Zhong et al. The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3–SRF axis
US20170184565A1 (en) P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses
Thongchot et al. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis
TW201929903A (zh) 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
US9207243B2 (en) Use of GLUT4 inhibitors and DNA damaging agents for treating multiple myeloma
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
US20090305225A1 (en) Inhibition of Creatine Uptake to Promote Weight Loss
US11000524B2 (en) Tyrosine kinase inhibition as a treatment for epilepsy
US20090325911A1 (en) Use of Androgens for the Treatment of Parkinson's Disease
US20090215681A1 (en) Methods of Diagnosis and Treatment of Metabolic Disorders
Stocchi Neuroprotection in Parkinson's disease: clinical trials
EP3335730A1 (en) Compounds for treating x-linked adrenoleukodystrophy
WO2017174626A1 (en) Methods and pharmaceutical compositions for inhibiting mast cell degranulation
WO2025137462A1 (en) Combination therapy for cancer
Ren et al. Overcoming Chemoresistance to Vemurafenib in Melanoma via Targeted Inhibition of PCK1 Using 3-mercaptopropionic Acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200428